Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance

Autor: Guangxian Mao, Zhimin Mu, Da Wu
Rok vydání: 2021
Předmět:
Male
Antimetabolites
Antineoplastic

Lung Neoplasms
animal structures
Biophysics
Adenocarcinoma of Lung
Exosomes
Biochemistry
ELAV-Like Protein 1
Phosphatidylinositol 3-Kinases
Cell Movement
Cell Line
Tumor

medicine
Humans
Neoplasm Invasiveness
RNA
Small Interfering

Lung cancer
Protein kinase B
PI3K/AKT/mTOR pathway
Cell Proliferation
A549 cell
Phosphoinositide 3-kinase
biology
Akt/PKB signaling pathway
Cell growth
Forkhead Transcription Factors
General Medicine
Transfection
Middle Aged
respiratory system
medicine.disease
Small Cell Lung Carcinoma
respiratory tract diseases
Gene Expression Regulation
Neoplastic

A549 Cells
Drug Resistance
Neoplasm

embryonic structures
Carcinoma
Squamous Cell

biology.protein
Cancer research
Female
RNA
Long Noncoding

Fluorouracil
Proto-Oncogene Proteins c-akt
Signal Transduction
Zdroj: Acta Biochimica et Biophysica Sinica. 53:1484-1494
ISSN: 1672-9145
DOI: 10.1093/abbs/gmab129
Popis: Long non-coding RNA (lncRNA) FOXD3-AS1 expression is upregulated in lung cancer; however, its effect and mechanism on 5-fluorouracil (5-FU) resistance remain unclear. In this study, we determined the effects of FOXD3-AS1-enriched exosomes derived from lung cancer cells on the proliferation, invasion, and 5-FU resistance of lung cancer cells. Online bioinformatics database analysis showed that FOXD3-AS1 was upregulated in lung cancer progression. Real-time quantitative PCR results confirmed that FOXD3-AS1 expression was upregulated in lung cancer tissues and cell lines, and FOXD3-AS1 was greatly enriched in lung cancer cell-derived exosomes. ELAV-like RNA-binding protein 1 (ELAVL1) was identified as an RNA-binding protein of FOXD3-AS1. The lung cancer cell-derived exosomes promoted A549 cell proliferation and invasion and inhibited apoptosis caused by 5-FU, and transfection of si-FOXD3-AS1 or si-ELAVL1 in exosome-incubated A549 cells reversed these effects. Moreover, exosome-incubated A549 cells were co-transfected with si-FOXD3-AS1 and pcDNA-ELAVL1, showing the same cell proliferation, invasion, and 5-FU resistance as those of A549 cells treated with lung cancer cell-derived exosomes alone. Mechanistic studies identified that lung cancer cell-derived exosomes activated the PI3K/Akt pathway, and transfection of si-FOXD3-AS1 or treatment with the PI3K inhibitor LY294002 reversed the activation of the PI3K/Akt axis induced by exosomes. In conclusion, our study revealed that lung cancer cell-derived exosomal FOXD3-AS1 upregulated ELAVL1 expression and activated the PI3K/Akt pathway to promote lung cancer progression. Our findings provide a new strategy for lung cancer treatment.
Databáze: OpenAIRE